Source: Pharmacological Research. Unidades: FM, FCF
Subjects: MELANOMA, METÁSTASE NEOPLÁSICA, EXPRESSÃO GÊNICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OLIVEIRA, Erica Aparecida de et al. TOP1 modulation during melanoma progression and in adaptative resistance to BRAF and MEK inhibitors. Pharmacological Research, v. 173, p. 1-11 art. 105911, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.phrs.2021.105911. Acesso em: 05 out. 2024.APA
Oliveira, E. A. de, Chauhan, J., Silva, J. R. da, Carvalho, L. A. da C., Dias, D., Carvalho, D. G. de, et al. (2021). TOP1 modulation during melanoma progression and in adaptative resistance to BRAF and MEK inhibitors. Pharmacological Research, 173, 1-11 art. 105911. doi:10.1016/j.phrs.2021.105911NLM
Oliveira EA de, Chauhan J, Silva JR da, Carvalho LA da C, Dias D, Carvalho DG de, Watanabe LRM, Rebecca VW, Mills G, Lu Y, Silva ASF da, Consolaro MEL, Herlyn M, Possik PA, Goding CR, Maria-Engler SS. TOP1 modulation during melanoma progression and in adaptative resistance to BRAF and MEK inhibitors [Internet]. Pharmacological Research. 2021 ; 173 1-11 art. 105911.[citado 2024 out. 05 ] Available from: https://doi.org/10.1016/j.phrs.2021.105911Vancouver
Oliveira EA de, Chauhan J, Silva JR da, Carvalho LA da C, Dias D, Carvalho DG de, Watanabe LRM, Rebecca VW, Mills G, Lu Y, Silva ASF da, Consolaro MEL, Herlyn M, Possik PA, Goding CR, Maria-Engler SS. TOP1 modulation during melanoma progression and in adaptative resistance to BRAF and MEK inhibitors [Internet]. Pharmacological Research. 2021 ; 173 1-11 art. 105911.[citado 2024 out. 05 ] Available from: https://doi.org/10.1016/j.phrs.2021.105911